The efficacy of current treatment regimens for pancreatic cancer (PC) remains unsatisfactory.
In recent years, immune checkpoint blockade (ICB) therapy has shown promising anti-tumor …

Immune checkpoint inhibitors (ICIs) represent a major breakthrough for cancer treatment.
However, evidence regarding the use of ICIs in pancreatic cancer (PC) remained scarce. To …

Background Among malignant neoplasm patients taking immune checkpoint inhibitors
(ICIs), it remains unknown how the systemic immune-inflammation index (SII) affects their …

The systemic immune-inflammation index (SII) is a significant prognostic factor in some
cancer types. However, the prognostic value of SII in patients with pancreatic cancer (PC) …

Background Systemic inflammation and immune dysfunction have been proved to be
associated with cancer progression and metastasis in various malignancies. The aim of this …

Background Pancreatic ductal adenocarcinoma (PDAC) detains a dismal prognosis and has
a limited number of prognostic factors. Inflammation has been demonstrated to play a key …

Background Immune checkpoint blockade (ICB) treatment may induce durable disease
remission, but only in a minority of patients with cancer. One important question is how to …

Immunotherapy has been recently considered as a promising alternative for cancer
treatment. Indeed, targeting of immune checkpoint (ICP) strategies have shown significant …

Background Emerging evidence has shown that intra-tumor immune features are associated
with response to immune checkpoint blockade (ICB) therapy. Accordingly, patient …

Pancreatic cancer is an extremely malignant tumor with the lowest 5-year survival rate
among all tumors. Pancreatic ductal adenocarcinoma (PDAC), as the most common …